Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jul 24;83(4):431–437. doi: 10.1054/bjoc.2000.1303

Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure

G Freyer 1, P Rougier 2, R Bugat 3, J-P Droz 4, M Marty 5, H Bleiberg 6, D Mignard 7, L Awad 7, P Herait 7, S Culine 8, V Trillet-Lenoir 1; the CPT-11 F205, F220, F221 and V222 study groups1
PMCID: PMC2374663  PMID: 10945486

Abstract

Our purpose was to determine, in patients with metastatic colorectal carcinoma treated with irinotecan single-agent after 5-FU failure, the most significant predictive parameters for tumour response, progression-free survival and toxicity. Between October 1992 and April 1995, 455 patients with 5-FU resistant metastatic colorectal carcinoma entered four consecutive phase II trials. The first two studies assessed tumour response, the other two were randomized studies which assessed the efficacy of racecadotril to prevent irinotecan-induced diarrhoea. Due to homogeneous main eligibility criterias, data from those studies could be pooled for statistical analysis. Potential clinical and biological predictive factors (PF) for toxicity, tumour growth control, e.g. response or stabilization and progression-free survival (PFS), were studied in multivariate analysis. 363 patients were evaluable for response, 432 were evaluable for PFS, 368 for neutropenia and 416 for delayed diarrhoea, respectively. Normal baseline haemoglobin level (Hb), time since diagnosis of colorectal carcinoma, grade 3 or 4 neutropenia or diarrhoea at first cycle and a low number of organs involved were the most PF for tumour growth control (P< 0.05). Significant prognostic variables for PFS were WHO Performance Status, liver and lymph-node involvement, time since diagnosis, age and CEA value (P≤ 0.02). Six groups of patients based on the number of unfavourable prognostic factors are presented. Baseline bilirubin, haemoglobin level, number of organs involved and time from diagnosis were PF for neutropenia; PS, serum creatinine, leukocyte count, time from 5-FU progression and prior abdominopelvic irradiation were PF for delayed diarrhoea (P≤ 0.05). These PF should help clinicians to anticipate for a given patient the probability to observe a response/stabilization or a toxicity. These results should also be prospectively confirmed in ongoing or future trials using irinotecan, both as a single agent and in combination with other drugs. © 2000 Cancer Research Campaign

Keywords: irinotecan, colorectal cancer, prognostic factors, survival, toxicity

Full Text

The Full Text of this article is available as a PDF (79.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahlgren J. D., Trocki O., Gullo J. J., Goldberg R., Muir W. A., Sisk R., Schacter L. Protracted infusion of 5-FU with weekly low-dose cisplatin as second-line therapy in patients with metastatic colorectal cancer who have failed 5-FU monotherapy. Cancer Invest. 1991;9(1):27–33. doi: 10.3109/07357909109032797. [DOI] [PubMed] [Google Scholar]
  2. Allen M., Cunningham D., Schmitt C. The importance of stabilization as an endpoint in the treatment of metastatic colorectal carcinoma: recent quality of life studies. Anticancer Drugs. 1998 Oct;9(9):783–790. doi: 10.1097/00001813-199810000-00007. [DOI] [PubMed] [Google Scholar]
  3. Canal P., Gay C., Dezeuze A., Douillard J. Y., Bugat R., Brunet R., Adenis A., Herait P., Lokiec F., Mathieu-Boue A. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol. 1996 Oct;14(10):2688–2695. doi: 10.1200/JCO.1996.14.10.2688. [DOI] [PubMed] [Google Scholar]
  4. Chabot G. G., Abigerges D., Catimel G., Culine S., de Forni M., Extra J. M., Mahjoubi M., Hérait P., Armand J. P., Bugat R. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol. 1995 Feb;6(2):141–151. doi: 10.1093/oxfordjournals.annonc.a059109. [DOI] [PubMed] [Google Scholar]
  5. Cunningham D., Pyrhönen S., James R. D., Punt C. J., Hickish T. F., Heikkila R., Johannesen T. B., Starkhammar H., Topham C. A., Awad L. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998 Oct 31;352(9138):1413–1418. doi: 10.1016/S0140-6736(98)02309-5. [DOI] [PubMed] [Google Scholar]
  6. Glimelius B., Hoffman K., Graf W., Påhlman L., Sjödén P. O. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Cancer. 1994 Feb 1;73(3):556–562. doi: 10.1002/1097-0142(19940201)73:3<556::aid-cncr2820730310>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  7. Nordic Gastrointestinal Tumor Adjuvant Therapy Group Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol. 1992 Jun;10(6):904–911. doi: 10.1200/JCO.1992.10.6.904. [DOI] [PubMed] [Google Scholar]
  8. Pitot H. C., Wender D. B., O'Connell M. J., Schroeder G., Goldberg R. M., Rubin J., Mailliard J. A., Knost J. A., Ghosh C., Kirschling R. J. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol. 1997 Aug;15(8):2910–2919. doi: 10.1200/JCO.1997.15.8.2910. [DOI] [PubMed] [Google Scholar]
  9. Rougier P., Bugat R., Douillard J. Y., Culine S., Suc E., Brunet P., Becouarn Y., Ychou M., Marty M., Extra J. M. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol. 1997 Jan;15(1):251–260. doi: 10.1200/JCO.1997.15.1.251. [DOI] [PubMed] [Google Scholar]
  10. Rougier P., Milan C., Lazorthes F., Fourtanier G., Partensky C., Baumel H., Faivre J. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Française de Cancérologie Digestive. Br J Surg. 1995 Oct;82(10):1397–1400. doi: 10.1002/bjs.1800821034. [DOI] [PubMed] [Google Scholar]
  11. Rougier P., Van Cutsem E., Bajetta E., Niederle N., Possinger K., Labianca R., Navarro M., Morant R., Bleiberg H., Wils J. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998 Oct 31;352(9138):1407–1412. doi: 10.1016/S0140-6736(98)03085-2. [DOI] [PubMed] [Google Scholar]
  12. Scheithauer W., Rosen H., Kornek G. V., Sebesta C., Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. 1993 Mar 20;306(6880):752–755. doi: 10.1136/bmj.306.6880.752. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. de Gramont A., Bosset J. F., Milan C., Rougier P., Bouché O., Etienne P. L., Morvan F., Louvet C., Guillot T., François E. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997 Feb;15(2):808–815. doi: 10.1200/JCO.1997.15.2.808. [DOI] [PubMed] [Google Scholar]
  14. de Gramont A., Vignoud J., Tournigand C., Louvet C., André T., Varette C., Raymond E., Moreau S., Le Bail N., Krulik M. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer. 1997 Feb;33(2):214–219. doi: 10.1016/s0959-8049(96)00370-x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES